A Bioequivalence Study of Sacubitril/Valsartan Film-coated Tablets Under Fasting Conditions

PHASE1Not yet recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

March 31, 2024

Primary Completion Date

April 30, 2024

Study Completion Date

August 31, 2024

Conditions

Chronic Heart Failure

Interventions

DRUG

Sacubitril and Valsartan Tablets 97mg/103mg

Each Tablet contains 97 mg of Sacubitril and 103 mg of Valsartan

DRUG

Entresto (Sacubitril and Valsartan Tablets 97mg/103mg)

Each Tablet contains 97.2 mg sacubitril and 102.8 mg valsartan as sodium salt complex

All Listed Sponsors

lead

Viatris Inc.

INDUSTRY